The Asia-Pacific Liver Cancer
Therapeutics Market was worth $97.24 million in 2016 and estimated to be
growing at a CAGR of 10.05%, to reach $156.96 million by 2021.
Recent advances in the treatment
for primary liver cancer might deliver some stimulating pointers mainly in the
Asian market where sickness and ethnic characteristics demand assessment.
In the Developing regions, such
as East and South-East Asia liver cancer is the third most common tumour and
the second primary cause of death. Treatment for liver cancer is reliant on
numerous factors such as size, type and age of the tumour and whether the
cancer has extended outside the liver.
Browse market data tables and
in-depth TOC of the Asia-Pacific
Liver Cancer Therapeutics Market to 2021 @ http://www.marketdataforecast.com/market-reports/asia-pacific-liver-cancer-therapeutics-market-839/
Asia Pacific characterises as
the fastest growing liver cancer treatment market owing to the rising geriatric
populations. This increasing number of liver cancer cases in the Asian
countries involves huge number of drugs for the treatment or prevention of
liver cancer and tumours. Further, growing healthcare expenditure and
increasing government initiatives are also augmenting the growth of this
market. Huge capital investment is a key restraint hindering the growth of the market.
Free sample of the report is
available @ http://www.marketdataforecast.com/market-reports/asia-pacific-liver-cancer-therapeutics-market-839/request-sample
The Asia-Pacific liver cancer
therapeutics market is segmented on the basis of type into primary, secondary
and benign liver growths. On the basis of therapeutics, the market is
bifurcated into hepatocellular carcinoma, Cholangio carcinoma, Hepatoblastoma
and targeted therapy. By end-use the market is divided amongst pediatrics and
adults. Hepatocellular Carcinoma is the largest segment for therapeutics type
due to the high prevalence of this type of liver cancer among people.
Inquire before buying @ http://www.marketdataforecast.com/market-reports/asia-pacific-liver-cancer-therapeutics-market-839/inquire
Based on geography the market is
analysed under various regions namely, China, India, Japan, South Korea and
Australia. China is the country in terms of revenue of the market for this
region while India and Japan are projected to grow at a high rate in the
forecast period.
Some of the key contributors in
the industry include Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx
Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc.,
Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG,
and Bristol-Myers Squibb Company.
About Us:
Market Data Forecast is a firm
working in the area of market research and business intelligence. With rich
experience in research across various business domains, we cater to the needs
of both individual and corporate clients. Our analyst team comprises expert
professionals in market research, who with their collective knowledge and
sksillset dedicatedly serve clients from various industries and regions.
Contact:
Abhishek Shukla
Sales Manager (International
Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail:
abhishek@marketdataforecast.com
No comments:
Post a Comment